Peginterferon and ribavirin treatment for hepatitis C virus infection

Table 1 Randomized, controlled trials for 48 wk vs 72 wk of peginterferon plus ribavirin in treatment-naïve patients infected with genotype 1 or 4

Authors	Country	Response criteria (time point) for randomization	Peg-IFNα/ribavirin	SVR rate in genotype 1 (48 wk vs 72 wk), n (%)	Difference (%)	P value	SVR rate in genotype 4 (48 wk vs 72 wk), n (%)
Sánchez-Tapias et al[57], 2006	Spain	Non-RVR (at wk 4)	2a: (180 μg/wk)/ 800 mg/d	41/149 (28) vs 63/142 (44)	16	0.003	12/16 (75) vs 10/19 (53)
Berg et al[56], 2006	Germany	Before treatment (Subgroup analysis for non-EVR)	2a: (180 μg/wk)/ 800 mg/d	17/100 (17) vs 31/106 (29)	12	0.040	-
Pearlman et al[58], 2007	USA	Slow response (at wk 24)	2b: (1.5 μg/kg per week)/ 800-1400 mg/d	9/49 (18) vs 20/52 (38)	20	0.026	-
Ferenci et al[61], 2010	Austria	EVR (at wk 12)	2a: (180 → 135 μg/wk)/ 1000-1200 mg/d	65/127 (51) vs 81/134 (60)	9	0.137	6/12 (50) vs 7/16 (44)

Peg-IFNα: Pegylated interferon α; SVR: Sustained virological response; RVR: Rapid virological response; EVR: Early virological response.